Ikarian Capital, LLC Reata Pharmaceuticals Inc Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$79.22 - $105.37 $5.95 Million - $7.91 Million	-75,092 Reduced 93.21%	5,472 $557,000
Q1 2023 May 15, 2023	BUY	$30.85 - $93.17 $2.49 Million - $7.51 Million	80,564 New	80,564 $7.32 Million
Q3 2022 Nov 14, 2022	SELL	$19.41 - $36.49 $324,942 - $610,879	-16,741 Reduced 80.47%	4,064 $102,000
Q2 2022 Aug 12, 2022	SELL	$20.71 - $36.5 $1.37 Million - $2.41 Million	-66,100 Reduced 76.06%	20,805 $632,000
Q1 2022 May 13, 2022	BUY	$24.12 - $39.6 $2.08 Million - $3.42 Million	86,305 Added 14384.17%	86,905 $2.85 Million
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $56,550 - $79,686	600 New	600 $60,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.